Atea Pharmaceuticals Inc.
AVIR
We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases. Our current product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which we believe has the poten…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$155M
▲ +6.0% YoY
Op. Margin
–
ROIC
-61.01%
▼ -9.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$141M
▲ +2.6% YoY
Op. Cash Flow (TTM)
-$141M
▲ +2.6% YoY
Net Debt
-$191M
Net Cash Position
Cash & Equiv.
$191M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with AVIR
Held by ETFs
AVIR is in 13 US ETFs. The largest of them, with AVIR's weight in each:
Atea Pharmaceuticals (AVIR) in three numbers
Questions about Atea Pharmaceuticals
Is Atea Pharmaceuticals a high-quality business?
Atea Pharmaceuticals scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 622.5%, and its weakest is return on capital at -61.0%. The Quality tab shows every check against its target.
Does Atea Pharmaceuticals (AVIR) pay a dividend?
No. Atea Pharmaceuticals (AVIR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 8.0% buyback yield. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in AVIR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AVIR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.